relapsed AML
Showing 76 - 100 of 6,742
AML Trial in Yanda (CAR-?dT)
Recruiting
- AML
- CAR-γδT
-
Yanda, Hebei, ChinaHebei yanda Ludaopei Hospital
Mar 11, 2021
AML Trial in Hangzhou (NKG2D CAR-NK)
Recruiting
- AML
- NKG2D CAR-NK
-
Hangzhou, Zhejiang, China
- +1 more
Feb 17, 2023
Leukemia, Myeloid, Acute Trial in Poznan (Liposomal Annamycin, Cytarabine)
Recruiting
- Leukemia, Myeloid, Acute
- Liposomal Annamycin
- Cytarabine
-
Bologna, Italy
- +4 more
Jan 31, 2023
Xospata in Relapsed or Refractory Acute Myeloid Leukemia With
Recruiting
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- Gilteritinib Exposure
-
Goyang-si, Gyeonggi-do, Korea, Republic of
- +4 more
Aug 18, 2022
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)
Recruiting
- Leukemia
- +19 more
- CYNK-001
-
Denver, Colorado
- +9 more
Sep 9, 2022
AML Trial in Hangzhou (MAX-40279-01)
Recruiting
- AML
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University
Jan 18, 2022
Newly-diagnosed APL (de Novo or Therapy-related), Relapsed APL Trial in Dresden (observational)
Recruiting
- Newly-diagnosed APL (de Novo or Therapy-related)
- Relapsed APL
- observational
-
Dresden, GermanyProf. Dr. U. Platzbecker
Aug 10, 2022
Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)
Active, not recruiting
- Acute Myeloid Leukemia
- +3 more
-
Edmonton, Alberta, Canada
- +1 more
Jan 31, 2023
Acute Myeloid Leukemia, in Relapse Trial in Baltimore, Chapel Hill (pembrolizumab,)
Active, not recruiting
- Acute Myeloid Leukemia, in Relapse
-
Baltimore, Maryland
- +1 more
Aug 10, 2022
AML, Adult Recurrent, MDS Trial in Durham (DVX201)
Recruiting
- AML, Adult Recurrent
- MDS
- DVX201
-
Durham, North CarolinaDuke University Hospital
Feb 11, 2022
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou
Recruiting
- Allogeneic Hematopoietic Stem Cell Transplantation
- +2 more
- VEN+AZA+Modified BUCY
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Apr 10, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (BP1002; Liposomal Bcl-2 Antisense
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
- Decitabine (in combination with BP1002)
- (no location specified)
Mar 8, 2022
Recurrent Acute Myeloid Leukemia Trial in Nashville (Venetoclax, Decitabine, Cedazuridine)
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- Venetoclax
- +4 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Mar 22, 2023
AML, Childhood Trial in United States (Nivolumab, 5-azacytidine)
Active, not recruiting
- AML, Childhood
-
Los Angeles, California
- +11 more
Oct 10, 2022
Acute Myeloid Leukemia Trial in Suzhou (CAV Regimen, MEC Regimen)
Recruiting
- Acute Myeloid Leukemia
- CAV Regimen
- MEC Regimen
-
Suzhou, Jiangsu, ChinaThe First Affliated Hospital of Soochow University
Dec 22, 2022
Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse Trial in Miami (Bomedemstat,
Recruiting
- Acute Myeloid Leukemia
- +2 more
-
Miami, FloridaUniversity of Miami
Dec 22, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Boston (Iadademstat, Gilteritinib Oral Tablet)
Recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- Iadademstat
- Gilteritinib Oral Tablet
-
Boston, Massachusetts
- +2 more
Jan 18, 2023
Myelodysplastic Syndrome, Acute Myeloid Leukemia Trial in Boston (Lenalidomide, Velcade)
Active, not recruiting
- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
-
Boston, Massachusetts
- +1 more
Jun 22, 2021
Relapsed Pediatric ALL, Relapsed Pediatric AML, Refractory Acute Myeloid Leukemia Trial in Kansas City (Daunorubicin)
Recruiting
- Relapsed Pediatric ALL
- +3 more
-
Kansas City, MissouriChildren's Mercy Hospital
Jul 1, 2022
Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, MDS Trial in Cleveland (CPX-351)
Recruiting
- Refractory Acute Myeloid Leukemia
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Mar 15, 2022